2026 Benchmark Report R&D Tax Credit Data and Statistics

Boast’s annual benchmark report features data from the previous tax season (2024), tracking trends for over $3.6b in R&D expenditures in the US and Canada. Understanding how much companies invest in R&D (and how much they recover through tax credit programs) has traditionally been guesswork. Most benchmarks rely on self-reported survey data or industry estimates that may not reflect reality.

This report is different. Based on 6,907 actual R&D tax credit claims representing $3.6 billion in tracked expenditures from 2,298 innovative companies across North America, these benchmarks reflect real transaction data, not estimates.

Over the past decade, Boast has processed billions of dollars in R&D expenditures through its platform, creating the most comprehensive dataset of R&D tax credit performance in North America. This intelligence spans both US federal and state programs alongside Canada’s SR&ED and Quebec’s CDAE initiatives, offering unprecedented visibility into how innovative companies fund breakthrough work through non-dilutive government incentives

Bottom quartile claimants: (under $52,274)

Typically represent early-stage startups with limited R&D teams or established businesses just beginning to claim credits. These companies often discover they qualify for significantly more once they understand the breadth of qualifying activities.

Mid-market performers: ($114,841-$217,542)

Usually operate with dedicated R&D teams of 5-15 people, investing 15-25% of revenue in product development. They’ve moved beyond first-time claims to multi-year strategies but may not yet optimize across federal and state/provincial programs.

Top quartile claimants: (above $217,542)

Run sophisticated R&D operations, often with 20+ technical employees. They pursue multi-jurisdiction strategies, claiming both federal and state/provincial credits, and maintain contemporaneous documentation that withstands audits while maximizing recovery.

New feature development, algorithm optimization, technical architecture improvements, database performance enhancements, integration with third-party systems

Treating routine maintenance as R&D, inadequate documentation of technological uncertainty, missing contractor expenditures

Software and internet companies represent the overwhelming majority of R&D tax credit claimants, accounting for 5,565 of 6,907 claims (80.6%). This dominance reflects both the massive growth in software development activity across North America and increasing awareness that software R&D qualifies for tax credits.

Software companies enjoy favorable treatment because development activities clearly map to R&D criteria: overcoming technical uncertainty, systematic experimentation, technological advancement. The low audit rate suggests government reviewers recognize legitimate software R&D when properly documented.

Process improvements, new product prototypes, material testing, equipment modifications, quality enhancement experiments, automation development

Claiming routine production troubleshooting, inadequate documentation of systematic experimentation, confusion between pilot production and R&D manufacturing companies face unique challenges in R&D tax credit claims, reflected in their elevated 16.84% audit rate. That’s more than 3x the software industry average. With 297 claims representing 4.3% of the dataset, manufacturers must carefully distinguish between R&D and routine production activities.

The elevated audit rate stems from government scrutiny around what constitutes genuine R&D versus normal manufacturing optimization. Successful manufacturing claims require meticulous documentation showing systematic experimentation with uncertain outcomes, not just incremental production improvements.

Circuit design, embedded systems development, sensor integration, power management optimization, physical prototyping, hardware-software integration

Inadequate tracking of prototype iterations, missing materials costs, unclear separation between design and production phases. Hardware and electronics companies occupy a middle ground between software’s documentation ease and manufacturing’s scrutiny challenges, with 245 claims (3.5%) showing a 13.06% audit rate.

Hardware R&D claims benefit from tangible artifacts—prototypes, schematics, test results—that provide concrete evidence of experimentation. However, companies must clearly distinguish between R&D phases and manufacturing preparation.

Diagnostic tool development, drug formulation, medical device prototypes, software for health analytics, laboratory process improvements, biomarker discovery

Claiming clinical trials as R&D (generally not eligible), inadequate separation of research and patient care, missing pre-clinical experimentation

Healthcare and biotech companies navigate perhaps the most complex R&D tax credit landscape, with 163 claims (2.4%) showing a 14.11% audit rate and specialized qualification criteria around clinical versus research activities.

The challenge for healthcare companies lies in distinguishing R&D (discovering new knowledge, developing novel technologies) from clinical application (applying existing knowledge to patient care). Pre-clinical research on novel approaches clearly qualifies; routine clinical work typically doesn’t.

Graphics engine development, AI for non-player characters, physics simulations, multiplayer infrastructure, procedural content generation, audio processing algorithms

Claiming content creation as R&D, inadequate technical documentation, confusing artistic work with technical development. Gaming and digital media companies face the highest audit rate of major industries at 20.93%, nearly 4x the software industry average, despite just 86 claims (1.2% of dataset) in this category.

The elevated audit rate likely stems from government skepticism about whether gaming involves genuine technical advancement or merely applies existing game development technologies. Companies must emphasize novel technical achievements, not content creation.

Small and medium businesses represent the overwhelming majority of R&D tax credit claimants at 6,227 companies (90% of dataset). With average expenditures of $446,000, SMBs typically operate lean R&D teams of 3-15 people, investing 15-30% of revenue in product development.

SMBs leverage R&D tax credits differently than larger enterprises. While big companies view credits as margin enhancement, SMBs treat them as essential funding—often the difference between extending runway by 6-12 months or facing a difficult fundraising environment. The average SMB claim of $89,000-$112,000 (based on typical 20-25% credit rates) can fund an additional engineer for a year or accelerate critical feature development.

Common SMB challenges:

THE SMB ADVANTAGE

Refundable credits mean pre-profit companies receive cash refunds even without tax liability, making R&D tax credits particularly valuable for startups investing before achieving significant revenue.

Mid-market companies (342 claims, 5% of dataset) show dramatically different R&D patterns, with average expenditures of $2.0 million—4.5x the SMB average. These companies typically operate R&D teams of 20-50 people and invest 10-20% of revenue in product development.

Mid-market companies approach R&D tax credits more strategically. They pursue multi-jurisdiction claims, maintain contemporaneous documentation through integrated systems, and recover credits representing 20-30% of total R&D expenditures.

Mid-market characteristics

Mid-market companies optimize across federal and state/provincial programs, understanding that comprehensive strategies yield 30-50% higher recovery than federal-only approaches.

Enterprise companies (26 claims, <1% of dataset) represent a small fraction of claimants but demonstrate the most sophisticated R&D tax credit strategies. With average expenditures of $702,000 in this dataset, enterprises typically pursue credits across multiple jurisdictions simultaneously.

Enterprise claims show several distinguishing characteristics:

WHY ENTERPRISE REPRESENTATION APPEARS LOW IN THIS DATASET

Many large companies work directly with Big 4 accounting firms or have in-house tax departments handling R&D credits. This dataset primarily captures companies using specialized R&D tax credit platforms, which tend to serve SMB and mid-market segments most effectively.

The longest delay occurs before companies even engage an R&D tax credit provider. Companies wait an average of 4+ months after fiscal year-end to begin their claim process, often due to lack of awareness, competing priorities, or uncertainty about qualification.

OPPORTUNITY

Engaging providers immediately at fiscal year-end accelerates timelines by months and ensures no qualifying activities are forgotten. Early engagement also allows for mid-year planning that can increase qualifying expenditures before year-end.

Once engaged, providers conduct technical reviews identifying qualifying activities, mapping projects to R&D criteria, and gathering supporting documentation. This phase involves interviewing technical teams, reviewing project documentation, and analyzing time allocation.

OPPORTUNITY

Companies with contemporaneous documentation (project tracking systems, time logs, technical specifications maintained throughout the year) can reduce this phase to 30-45 days. Those reconstructing documentation after-the-fact face 90+ day timelines.

Financial reviews validate expenditure calculations, reconcile payroll data, verify contractor costs, and ensure claims align with accounting records. Median duration is just 9 days, but mean of 33 days suggests some claims face significant reconciliation challenges.

OPPORTUNITY

Clean financial data with clear cost center allocations and project-level tracking accelerates this phase. Companies lacking project-based accounting face extended financial reconciliation.

After approval, providers finalize documentation, complete government forms, and submit claims. The gap between approval and filing often reflects queuing for final review or waiting for optimal filing timing.

Once filed, government agencies review claims and issue Notices of Assessment. Median processing time is 63 days, but complex claims or those triggering additional review can extend to 150+ days.

KEY INSIGHT

From fiscal year-end to receiving credits takes 315 days on average. Companies that engage providers early, maintain contemporaneous documentation, and organize financial data effectively can compress this to 200-240 days, recovering credits 2-3 months faster.

STRATEGIC INSIGHT

Time is money in R&D tax credits. A company recovering $200,000 annually that reduces their timeline from 315 days to 240 days accelerates cash flow by 2.5 months, worth $5,000-$10,000 in opportunity cost depending on capital costs.

With 455 audits among 6,907 claims, the overall 6.59% audit rate demonstrates that government review remains the exception, not the rule. This rate aligns with industry benchmarks, suggesting Boast customers face typical audit exposure, neither elevated nor reduced compared to the broader market.

What triggers audits? While specific triggers remain proprietary to government agencies, patterns emerge from the data:

Audit duration: When audits occur, they average 93 days (median: 89 days) from opening to closure. This 3-month timeline demands organized documentation and responsive communication but typically doesn’t derail operations.

Audit outcomes: Among audited claims with complete data, companies secured average credits of $214,941 (median: $113,079), demonstrating that audits don’t necessarily mean rejection. They often result in full or substantial approval after review.

Company size dramatically influences audit probability, with mid-market companies facing 20% audit rates compared to just 0.69% for small, unassigned tier customers.

Over 11 years of processing R&D tax credit claims, Boast has built the most comprehensive platform for R&D tax credit optimization in North America. The numbers tell the story: